{
    "Clinical Trial ID": "NCT02186015",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cholecalciferol",
        "  Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.",
        "INTERVENTION 2: ",
        "  No Cholecalciferol",
        "  Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Metastatic breast cancer (Stage IV)",
        "  Histologically confirmed estrogen receptor positive disease",
        "  Female",
        "  Serum 25(OH) <30 ng/ml",
        "  Age  18 years",
        "  Pre or post-menopausal",
        "  ECOG Performance status 0-2",
        "  Adequate organ function as defined as GFR> 30 mls/min and serum calcium  10.4 mg/dl",
        "  Any race/ethnicity",
        "  English speaking",
        "  No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician",
        "  Willingness to sign a written informed consent and complete questionnaires",
        "  Cease ingestion of vitamin D supplementation not study related",
        "Exclusion Criteria:",
        "  Women with Stage I-III breast cancer",
        "  Serum 25(OH)D levels  30 ng/ml",
        "  Untreated CNS involvement",
        "  History of kidney stones",
        "  History of renal failure",
        "  History of hyperparathyroidism",
        "  History of hypersensitivity to vitamin D",
        "  Non-English speaking",
        "  Currently pregnant or lactating, or anticipating pregnancy",
        "  Unwilling to cease ingestion of calcium supplements (>1000 mg/d)",
        "  Unwilling or unable to complete informed consent or study questionnaires",
        "  Psychiatric or other clinical conditions that preclude study compliance",
        "  Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Serum 25(OH)D",
        "  Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.",
        "  Time frame: 0, 8 weeks",
        "Results 1: ",
        "  Arm/Group Title: Cholecalciferol",
        "  Arm/Group Description: Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.",
        "  Overall Number of Participants Analyzed: 10",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: ng/ml  32        (22 to 40)",
        "Results 2: ",
        "  Arm/Group Title: No Cholecalciferol",
        "  Arm/Group Description: Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention.",
        "  Overall Number of Participants Analyzed: 0",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: ng/ml  "
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/11 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}